Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2618 and Penpulimab in Relapsed/Refractory Lymphoma
NCT05400876Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2022
- Primary completion
- May 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2618 in Hodgkin lymphoma (HL), B-cell non-Hodgkin lymphoma, T-cell non-Hodgkin lymphoma, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
TQB2618
03
Conditions
Hodgkin lymphoma (HL)B-cell non-Hodgkin lymphomaT-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05400876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05400876.